Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization/ER, fluvo.. 19% Improvement Relative Risk Hospitalization/ER, FIA.. 12% Hospitalization/ER, SSRI 12% Hospitalization/ER, all a.. 10% Fritz et al. Fluvoxamine for COVID-19 Prophylaxis Is prophylaxis with fluvoxamine beneficial for COVID-19? Retrospective 25,034 patients in the USA (March 2020 - May 2021) Study underpowed for fluvoxamine, only 17 patients Fritz et al., Translational Psychiatry, doi:10.1038/s41398-022-02109-3 Favors fluvoxamine Favors control
Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2
Fritz et al., Translational Psychiatry, doi:10.1038/s41398-022-02109-3
Fritz et al., Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2, Translational Psychiatry, doi:10.1038/s41398-022-02109-3
Aug 2022   Source   PDF  
  All Studies   Meta
Retrospective 25,034 COVID+ outpatients showing significantly lower ER/hospitalization with antidepressants and FIASMA antidepressants, and a dose-dependent response.
risk of hospitalization/ER, 19.4% lower, RR 0.81, p = 0.69, treatment 4 of 17 (23.5%), control 1,896 of 20,457 (9.3%), adjusted per study, odds ratio converted to relative risk, fluvoxamine, multivariable.
risk of hospitalization/ER, 11.9% lower, RR 0.88, p = 0.03, treatment 707 of 3,414 (20.7%), control 1,896 of 20,457 (9.3%), adjusted per study, odds ratio converted to relative risk, FIASMA, multivariable.
risk of hospitalization/ER, 11.9% lower, RR 0.88, p = 0.04, treatment 559 of 2,744 (20.4%), control 1,896 of 20,457 (9.3%), adjusted per study, odds ratio converted to relative risk, SSRI, multivariable.
risk of hospitalization/ER, 10.1% lower, RR 0.90, p = 0.04, treatment 971 of 4,577 (21.2%), control 1,896 of 20,457 (9.3%), adjusted per study, odds ratio converted to relative risk, all antidepressants, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fritz et al., 22 Aug 2022, retrospective, USA, peer-reviewed, 5 authors, study period 1 March, 2020 - 16 May, 2021.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFluvoxamineAll
Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2
Bradley A Fritz, Nicolas Hoertel, Eric J Lenze, Farid Jalali, Angela M Reiersen
Translational Psychiatry, doi:10.1038/s41398-022-02109-3
Antidepressants have previously been associated with better outcomes in patients hospitalized with COVID-19, but their effect on clinical deterioration among ambulatory patients has not been fully explored. The objective of this study was to assess whether antidepressant exposure was associated with reduced emergency department (ED) or hospital visits among ambulatory patients with SARS-CoV-2 infection. This retrospective cohort study included adult patients (N = 25 034) with a positive SARS-CoV-2 test performed in a non-hospital setting. Logistic regression analyses tested associations between home use of antidepressant medications and a composite outcome of ED visitation or hospital admission within 30 days. Secondary exposures included individual antidepressants and antidepressants with functional inhibition of acid sphingomyelinase (FIASMA) activity. Patients with antidepressant exposure were less likely to experience the primary composite outcome compared to patients without antidepressant exposure (adjusted odds ratio [aOR] 0.89, 95% CI 0.79-0.99, p = 0.04). This association was only observed with daily doses of at least 20 mg fluoxetine-equivalent (aOR 0.87, 95% CI 0.77-0.99, p = 0.04), but not with daily doses lower than 20 mg fluoxetine-equivalent (aOR 0.94, 95% CI 0.80-1.11, p = 0.48). In exploratory secondary analyses, the outcome incidence was also reduced with exposure to selective serotonin reuptake inhibitors (aOR 0.87, 95% CI 0.75-0.99, p = 0.04), bupropion (aOR 0.70, 95% CI 0.55-0.90, p = 0.005), and FIASMA antidepressant drugs (aOR 0.87, 95% CI 0.77-0.99, p = 0.03). Antidepressant exposure was associated with a reduced incidence of emergency department visitation or hospital admission among SARS-CoV-2 positive patients, in a dose-dependent manner. These data support the FIASMA model of antidepressants' effects against COVID-19.
AUTHOR CONTRIBUTIONS Dr. Fritz had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Fritz, Lenze, Reiersen. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Fritz. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Fritz. Administrative, technical, or material support: Lenze, Reiersen. COMPETING INTERESTS ADDITIONAL INFORMATION Supplementary information The online version contains supplementary material available at Correspondence and requests for materials should be addressed to Bradley A. Fritz. Reprints and permission information is available at reprints Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Althaus, Marini, Zlamal, Pelzl, Singh et al., Antibodyinduced procoagulant platelets in severe COVID-19 infection, Blood
Bayat, Ryono, Phelps, Geis, Sedghi et al., Reduced mortality with ondansetron use in SARS-CoV-2-infected inpatients, Open Forum Infect Dis
Brody, Gu, Antidepressant Use Among Adults: United States
Carpinteiro, Edwards, Hoffmann, Kochs, Gripp et al., Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells, Cell Rep. Med
Carpinteiro, Gripp, Hoffmann, Pöhlmann, Hoertel et al., Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells, J Biol Chem
Clelland, Ramiah, Steinberg, Clelland, Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort, BJPsych Open
Cloutier, Allaeys, Marcoux, Machlus, Mailhot et al., Platelets release pathogenic serotonin and return to circulation after immune complexmediated sequestration, Proc Natl Acad Sci
Dechaumes, Nekoua, Belouzard, Sane, Engelmann et al., Fluoxetine Can Inhibit SARS-CoV-2 in vitro, Microorganisms
Dhir, Kulkarni, Possible involvement of sigma-1 receptors in the antiimmobility action of bupropion, a dopamine reuptake inhibitor, Fundam Clin Pharm
Ettman, Abdalla, Cohen, Sampson, Vivier et al., Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic, JAMA Netw Open
Facente, Reiersen, Lenze, Boulware, Klausner, Fluvoxamine for the early treatment of SARS-CoV-2 infection: a review of current evidence, Drugs
Hashimoto, Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor, Eur Arch Psychiatry Clin Neurosci
Hashimoto, Suzuki, Hashimoto, Mechanisms of action of fluvoxamine for COVID-19: a historical review, Mol Psychiatry
Hayasaka, Purgato, Magni, Ogawa, Takeshima et al., Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials, J Affect Disord
Hergovich, Aigner, Eichler, Entlicher, Drucker et al., Paroxetine decreases platelet serotonin storage and platelet function in human beings, Clin Pharm Ther
Herr, Bode, Duerschmied, The effects of serotonin in immune cells, Front Cardiovasc Med
Hoehn, Jernigan, Japtok, Chang, Midura et al., Acid Sphingomyelinase Inhibition in Stored Erythrocytes Reduces Transfusion-Associated Lung Inflammation, Ann Surg
Hoertel, Blachier, Blanco, Olfson, Massetti et al., A stochastic agent-based model of the SARS-CoV-2 epidemic in France, Nat Med
Hoertel, Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19?, JAMA Netw Open
Hoertel, Sánchez-Rico, Gulbins, Kornhuber, Carpinteiro et al., Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study, Transl Psychiatry
Hoertel, Sánchez-Rico, Gulbins, Kornhuber, Carpinteiro et al., Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study, Clin Pharm Ther
Hoertel, Sánchez-Rico, Gulbins, Kornhuber, Vernet et al., Association between benzodiazepine receptor agonist use and mortality in patients hospitalized for COVID-19: a multicenter observational study, Epidemiol Psychiatric Sci
Hoertel, Sánchez-Rico, Herrera-Morueco, De La Muela, Gulbins et al., Comorbid medical conditions are a key factor to understand the relationship between psychiatric disorders and COVID-19-related mortality: results from 49,089 COVID-19 inpatients, Mol. Psychiatry
Hoertel, Sánchez-Rico, Muela, Abellán, Blanco et al., Risk of death in individuals hospitalized for COVID-19 with and without psychiatric disorders: an observational multicenter study in France, Biol. Psychiatry Glob Open Sci, doi:10.1016/j.bpsgos.2021.12.007
Hoertel, Sánchez-Rico, Vernet, Beeker, Jannot et al., Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, Mol Psychiatry
Hoertel, Sánchez-Rico, Vernet, Beeker, Neuraz et al., Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study, Br J Clin Pharm
Hoertel, Sánchez-Rico, Vernet, Jannot, Neuraz et al., Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19, Clin Drug Investig
Hoertel, Sánchez-Rico, Vernet, Jannot, Neuraz et al., Observational study of haloperidol in hospitalized patients with COVID-19, PLoS ONE
Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in hospitalized patients with Covid-19, N. Engl J Med
Ishima, Fujita, Hashimoto, Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells, Eur J Pharm
Kast, Anti-and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels, Gen Hosp Psychiatry
Khodadoust, Inferring a causal relationship between ceramide levels and COVID-19 respiratory distress, Sci Rep
Kopczyńska, Szereda-Przestaszewska, 5HT2 and 5HT3 receptors' contribution to modeling of post-serotonin respiratory pattern in cats, Life Sci
Kornhuber, Hoertel, Gulbins, The acid sphingomyelinase/ceramide system in COVID-19, Mol Psychiatry
Kornhuber, Muehlbacher, Trapp, Pechmann, Friedl et al., Identification of novel functional inhibitors of acid sphingomyelinase, PLoS ONE
Kornhuber, Tripal, Reichel, Terfloth, Bleich et al., Identification of new functional inhibitors of acid sphingomyelinase using a structure-propertyactivity relation model, J Med Chem
Köhler, Freitas, Stubbs, Maes, Solmi et al., Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis, Mol Neurobiol
Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial, Jama
Luber, Meyers, Williams-Russo, Hollenberg, Didomenico et al., Depression and service utilization in elderly primary care patients, Am J Geriatr Psychiatry
Macfadden, Brown, Buchan, Chung, Kozak et al., Screening large population health databases for potential coronavirus disease 2019 therapeutics: a pharmacopeia-wide association study of commonly prescribed medications, Open Forum Infect Dis
Marín-Corral, Rodríguez-Morató, Gomez-Gomez, Pascual-Guardia, Muñoz-Bermúdez et al., Metabolic signatures associated with severity in hospitalized COVID-19 patients, Int J Mol Sci
Mühle, Kremer, Vetter, Schmid, Achenbach et al., COVID-19 and its clinical severity are associated with alterations of plasma sphingolipids and enzyme activities of sphingomyelinase and ceramidase, medRxiv, doi:10.1101/2022.01.19.22269391
Nishikawa, Kanno, Zhou, Xiao, Suzuki et al., Massive imagebased single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19, Nat Commun
Oskotsky, Maric, Tang, Oskotsky, Wong et al., Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants, JAMA Netw Open
Pandhare, Pappu, Wilms, Blanton, Jansen, The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors, Neuropharmacology
Rabeea, Merchant, Khan, Kow, Hasan, Surging trends in prescriptions and costs of antidepressants in England amid COVID-19, Daru
Reis, Santos Moreira-Silva, Silva, Thabane, Milagres et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health
Rico, Cougoule, Gulbins, Kornhuber, Carpinteiro, Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms, Mol Psychiatry
Ritchie, Matieu, Rodés-Guirao, Appel, Giattino et al., Coronavirus pandemic (COVID-19) vaccinations
Roweth, Yan, Bedwani, Chauhan, Fowler et al., Citalopram inhibits platelet function independently of SERT-mediated 5-HT transport, Sci Rep
Sawada, Uchida, Suzuki, Watanabe, Kikuchi et al., Persistence and compliance to antidepressant treatment in patients with depression: a chart review, BMC Psychiatry
Schloer, Brunotte, Goretzko, Mecate-Zambrano, Korthals et al., Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine, Emerg Microbes Infect
Schloer, Brunotte, Mecate-Zambrano, Zheng, Tang et al., Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro, Br J Pharm
Seftel, Boulware, Prospective cohort of fluvoxamine for early treatment of Coronavirus Disease 19, Open Forum Infect Dis
Singh, Parida, Lingaraju, Kesavan, Kumar et al., Drug repurposing approach to fight COVID-19, Pharm Rep
Sukhatme, Reiersen, Vayttaden, Sukhatme, Fluvoxamine: a review of its mechanism of action and its role in COVID-19, Front Pharm
Torretta, Garziano, Poliseno, Capitanio, Biasin et al., Severity of COVID-19 Patients Predicted by Serum Sphingolipids Signature, Int J Mol Sci
Vai, Mazza, Colli, Foiselle, Allen et al., Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis, Lancet Psychiatry
Van Walraven, Austin, Jennings, Quan, Forster, A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data, Med Care
Venkatesan, Repurposing drugs for treatment of COVID-19, Lancet Respir Med
Von Elm, Altman, Egger, Pocock, Gøtzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Lancet
Zaid, Guessous, Puhm, Elhamdani, Chentoufi et al., Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19, Blood Adv
Zimniak, Kirschner, Hilpert, Geiger, Danov et al., The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue, Sci Rep
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop